Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

Tait D. Shanafelt,Xin V. Wang,Neil E. Kay,Curtis A. Hanson,Susan O'Brien,Jacqueline C. Barrientos,Diane F. Jelinek,Esteban Braggio,Jose F. Leis,Cong C. Zhang,Steven Coutre,Paul M. Barr,Amanda F. Cashen,Anthony R. Mato,Avina K. Singh,Michael P. Mullane,Richard F. Little,Harry P. Erba,Richard Stone,Mark R. Litzow,Martin S. Tallman

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

2019

Abstract Background Data regarding the efficacy of treatment with ibrutinib–rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients wi...

Keywords:

Chronic lymphocytic leukemia
Surgery
Chemoimmunotherapy
Rituximab
Oncology
Fludarabine
Diabetes mellitus
Ibrutinib
Internal medicine
Cyclophosphamide
Medicine
Progression-free survival
Leukemia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

261

Citations